ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 276,73
-0,73%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Altimmune Inc (ALT)

  7. Altimmune Inc (ALT) Actualités

ALT Altimmune Inc

7,20
0,00 (0,00%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Altimmune Inc ALT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 7,20 00:15:55
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
7,18 6,90 7,42 7,26 7,20
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202423:24GLOBEAltimmune Statement on the Passing of Dr. Stephen Harrison
27/3/202412:00GLOBEAltimmune Announces Positive Lean Mass Preservation Data for..
27/3/202411:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
20/3/202412:30GLOBEAltimmune to Report Fourth Quarter and Full Year 2023..
14/2/202418:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202412:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202417:49EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/1/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202413:30GLOBEAltimmune Announces Presentation of Pemvidutide Clinical..
08/12/202314:35GLOBEWater Tower Research US Climate Virtual Investor Conference:..
04/12/202314:35GLOBEWater Tower Research US Climate Investor Conference Agenda..
30/11/202322:28EDGAR2Form 8-K - Current report
30/11/202322:24GLOBEAltimmune Announces Positive Topline Results from MOMENTUM..
07/11/202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:06EDGAR2Form 8-K - Current report
07/11/202313:00GLOBEAltimmune Announces Third Quarter 2023 Financial Results and..
31/10/202312:30GLOBEAltimmune to Report Third Quarter 2023 Financial Results and..
26/10/202314:15DJNAltimmune Gets FDA Fast-Track Designation for Pemvidutide in..
26/10/202313:30GLOBEAltimmune Granted Fast Track Designation by FDA for..
25/10/202313:30GLOBEAltimmune to Present New Data on the Anti-Inflammatory and..
17/10/202313:30GLOBEAltimmune to Participate at Two Upcoming Investor..
29/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202322:55EDGAR2Form 8-K - Current report
26/9/202313:30GLOBEAltimmune Announces Oral Presentation of Pemvidutide..
12/9/202313:30GLOBEAltimmune Announces Completion of Dosing in the Phase 2..
30/8/202313:30GLOBEAltimmune to Participate at Two Upcoming Investor..
16/8/202322:14EDGAR2Form ARS - Annual Report to Security Holders
16/8/202322:10EDGAR2Form DEF 14A - Other definitive proxy statements
16/8/202300:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:04EDGAR2Form 8-K - Current report
10/8/202313:00GLOBEAltimmune Announces Second Quarter 2023 Financial Results..

Dernières Valeurs Consultées

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés